Sustained first remission in an adolescent with hepatosplenic T‐cell lymphoma treated with T‐cell leukemia induction, nucleoside analog‐based consolidation, and early hematopoietic stem cell transplant | Zendy

Schafer Eric | Zendy; Chen Allen | Zendy; Arceci Robert J. | Zendy

Premium

Sustained first remission in an adolescent with hepatosplenic T‐cell lymphoma treated with T‐cell leukemia induction, nucleoside analog‐based consolidation, and early hematopoietic stem cell transplant

Author(s) -

Schafer Eric,

Chen Allen,

Arceci Robert J.

Publication year - 2009

Publication title -

pediatric blood and cancer

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 1.116

H-Index - 105

eISSN - 1545-5017

pISSN - 1545-5009

DOI - 10.1002/pbc.22129

Subject(s) - medicine , lymphoma , leukemia , oncology , chemotherapy , hematopoietic stem cell transplantation , regimen , stem cell , transplantation , nucleoside analogue , haematopoiesis , immunology , cancer research , nucleoside , genetics , stereochemistry , chemistry , biology

Hepatosplenic T‐cell lymphoma (HTCL) is a rare malignancy. Prognosis is poor with only a few case reports of long‐term survivors. While HTCL universally involves the bone marrow, the condition has been most often treated with multimodal lymphoma specific chemotherapy. We report a durable, sustained first remission in an adolescent treated for HTCL who received induction therapy according to a high risk T‐cell leukemia regimen, a nucleoside analog‐based consolidation, and allogeneic transplantation associated with GVHD. Pediatr Blood Cancer 2009;53:1127–1129. © 2009 Wiley‐Liss, Inc.

This content is not available in your region!

Continue researching here.

Having issues? You can contact us here

Accelerating Research